Cullinan Therapeutics Files DEFA14A Proxy Materials
Ticker: CGEM · Form: DEFA14A · Filed: Apr 28, 2026 · CIK: 0001789972
| Field | Detail |
|---|---|
| Company | Cullinan Therapeutics, Inc. (CGEM) |
| Form Type | DEFA14A |
| Filed Date | Apr 28, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-materials, sec-filing
TL;DR
Cullinan Therapeutics dropped more proxy docs on 4/28/26. Check it.
AI Summary
Cullinan Therapeutics, Inc. filed a Definitive Additional Materials (DEFA14A) on April 28, 2026. The filing, with SEC Accession Number 0001193125-26-183472, contains additional proxy soliciting materials. The company's principal executive offices are located at One Main Street, Suite 1350, Cambridge, MA 02142.
Why It Matters
This filing indicates that Cullinan Therapeutics is providing additional information to shareholders related to proxy solicitations, which could pertain to upcoming shareholder votes or corporate actions.
Risk Assessment
Risk Level: low — This filing is a routine proxy material submission and does not inherently indicate new risks for the company.
Key Players & Entities
- Cullinan Therapeutics, Inc. (company) — Filer
- 0001193125-26-183472 (filing_id) — SEC Accession Number
- 2026-04-28 (date) — Filing Date
- ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 (address) — Mailing and Business Address
FAQ
What type of filing is this DEFA14A?
This DEFA14A filing is for Additional definitive proxy soliciting materials and Rule 14(a)(12) material.
What is the SEC Accession Number for this filing?
The SEC Accession Number for this filing is 0001193125-26-183472.
When was this filing accepted by the SEC?
This filing was accepted on 2026-04-28 at 06:54:21.
What is Cullinan Therapeutics, Inc.'s business address?
Cullinan Therapeutics, Inc.'s business address is ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142.
What is the CIK number for Cullinan Therapeutics, Inc.?
The CIK number for Cullinan Therapeutics, Inc. is 0001789972.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 28, 2026 regarding Cullinan Therapeutics, Inc. (CGEM).